Chester County News and Community Website
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug that acts as a covalent inhibitor of two key immune signaling kinases, ITK …
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 Inhibitor Read More
MALVERN, PA — MAXONA Pharmaceuticals has officially emerged from stealth mode, announcing the successful completion of its U.S. Phase 1 clinical trials for MAX-001, a groundbreaking non-opioid, non-NSAID oral therapy designed …
MAXONA Pharmaceuticals Completes Phase 1 Trials for Breakthrough Pain Therapy Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced the expansion of SELVA, its Phase 3 clinical trial of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), to include children as young …
Palvella Therapeutics Expands Phase 3 Trial to Younger Patients Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has initiated its pivotal Phase 3 clinical trial evaluating buntanetap as a treatment for early Alzheimer’s disease (AD), marking an important step forward …
Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap Read More
MALVERN, PA — Biopharmaceutical company Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for OCU500, a novel …
Ocugen Receives FDA Greenlight for Phase 1 Trial of Mucosal COVID-19 Vaccine Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a potential treatment for diabetic macular edema …
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for OCU400, a groundbreaking gene therapy targeting retinitis pigmentosa …
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations …
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease Read More
BERWYN, PA — AscellaHealth has unveiled its Specialty & Rare Pipeline Digest™, a comprehensive digital resource aimed at providing critical information on specialty and rare disease drug launches, biosimilars, and cell …
AscellaHealth Introduces Specialty & Rare Pipeline Digest to Advance Healthcare Insights Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced that the first group of patients has been dosed in a pivotal Phase 2 clinical trial evaluating its QTORIN™ 3.9% rapamycin …
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment Read More